Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts.
Get premium news and insight, AI stock picks, and deep research tools by upgrading to InvestingPro - get 55% off today
The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says, emphasising that it is built “bottom up” and reflects “our analysts’ most favored and some of their most differentiated ideas.”
According to the firm, the new No. 1 additions for December are DraftKings, Brinker International, Terns Pharmaceuticals, ADMA Biologics, CVS Health, DuPont de Nemours, Macerich, and Synopsys.
These join a broader roster of 27 Top Picks across 6 sectors, with each stock selected based on a 12-month outlook and supported by a clearly defined investment thesis.
For DraftKings, the firm said it believes “you should buy DKNG here,” while it stated that Brinker’s “value leadership positions Chili’s to sustain same-store sales growth outperformance and traffic share gains.”
Meanwhile, Terns is now seen as a “simpler and cleaner story,” and CVS is a top pick “due to the estimated $3.00 of embedded earnings power mostly driven by successful execution on margin recovery in the health insurance segment.”
The analysts also flag areas where they are more bullish than the market. Stocks where Mizuho’s rating is “more Bullish than consensus” include First Industrial Realty Trust and Macerich, while names where its price target is “10% or greater than consensus” include First Solar, Vaxcyte, and Arcutis Biotherapeutics.
